

NEW MEXICO
OIL CONSERVATION COMMISSION
AZTEC, NEW MEXICO

August 21, 1956

Mr. Warren Nankin
Oil Conservation Commission
Santa Fe, New Mexico

Dear Warren:

Reference is made to dual completion order #337 which you have indicated you will issue August 28, 1956.

As you may remember, you have sent me a copy of Amerada's application, with a pencilled note at the top asking me if it is okay to issue. You are aware from your note that I wrote Amerada on July 24th., 1956, enclosing copy of our dual completion memorandum, instructing them to secure tentative approval prior to dually completing the well. Evidently they misunderstood the instructions, as we have received nothing in this office pertaining to this dual completion prior to the copy of the final application which you have sent to us. However, I have looked over their application and insofar as I can see they have complied with all the requirements of our dual completion order with the exception they didn't secure tentative approval prior to drilling the well. It would be rather difficult for us to make them back-track at this stage. Therefore, I will leave the matter of approval of the dual completion order strictly in your hands and I assure you that you will have my blessings whatever you do.

I am writing Amerada another letter instructing them in the proper procedure for securing approval of dual completions and will send you a copy.

Yours very truly,

Emery C. Arnold
Supervisor, District #3

ECA/lb

0341, 12 Tempa

State of New Jersey
Department of Education
Division of Office Management & Information Technology

12-000000-1000

0001 01 August 1961 1145 hrs

will have my pleasure whenever you do. I am glad to hear that you are well and hope you are enjoying your vacation. I will leave the matter of approval of the book to you. It would be rather difficult for me to make them back-track and will. Therefore, I will leave the matter of approval of the book to you. I am glad to hear that you are well and hope you are enjoying your vacation. I will leave the matter of approval of the book to you. I am glad to hear that you are well and hope you are enjoying your vacation. I will leave the matter of approval of the book to you.

I am writing another letter instructing them to the proper
you have like has techniques such to everyone gathered and embraced.

yours

First you can

SECRET

2402

OCC
A2tec

Emergency is this
MAIN OFFICE OGC

AUG 10 1956

8:25

Don't believe
they requested
preliminary
approval?

DC-337

sent 8/23/56

Drawer D
Monument, New Mexico
August 10, 1956

New Mexico Oil Conservation Commission
P. O. Box 871
Santa Fe, New Mexico

you wrote
them on
7/24/56
to apply!

Re: Application to Dually Complete
Amerada Jicarilla Apache "F"
No. 2, Rio Arriba County,
New Mexico

South Blanco P.C. not
undesignated La Ventana


Gentlemen:

By this letter of application Amerada Petroleum Corporation
wishes to state the following:

- (A) That Amerada Petroleum Corporation Jicarilla Apache "F" No. 2 is located 990 ft. FNL and 990 ft. FWL of Section 17, Township 25 North, Range 5 West, Rio Arriba County, New Mexico. The attached Exhibit A shows the location of all offset wells.
- (B) That the subject well has 5-1/2" casing set at 3790 ft. and cemented with 300 sacks of cement.
- (C) That the applicant dually completed the well in the following manner:
 - (1) Perforated the 5-1/2" casing in the interval from 2721 ft. to 2725 ft., 2735 ft. to 2742 ft., and 2762 ft. to 2784 ft. in the Pictured Cliff zone.
 - (2) Perforated the 5-1/2" casing in the interval from 3594 ft. to 3621 ft. and 3709 ft. to 3716 ft. in the La Ventana zone.
 - (3) Set production type packer between these zones at 3483 ft. for separation.
 - (4) Produced the La Ventana gas through the tubing and the Pictured Cliff gas through the casing annulus. The attached Exhibit B is a diagrammatic sketch of the dual completion.

I note that
the R-110 for
the P.C.
was undesignated
however, it is
within one mile
of South Blanco!

(m)



[illegible]

the 1990s, the number of people in the United States who are 65 years of age or older is projected to increase from 20 million to 30 million, and the number of people 75 years of age or older is projected to increase from 10 million to 15 million (U.S. Census Bureau, 1996). The number of people 85 years of age or older is projected to increase from 2 million to 4 million (U.S. Census Bureau, 1996). The number of people 90 years of age or older is projected to increase from 500,000 to 1 million (U.S. Census Bureau, 1996). The number of people 95 years of age or older is projected to increase from 100,000 to 200,000 (U.S. Census Bureau, 1996). The number of people 100 years of age or older is projected to increase from 10,000 to 20,000 (U.S. Census Bureau, 1996).

1980-81 (continued)

As a result, the model is able to capture the effects of the various factors on the dependent variable.

97-100

14. 0.1. 1. 1. 1.

1994). The authors also found that the effect of the type of information on the choice of the type of information was significant. The effect of the type of information on the choice of the type of information was significant. The effect of the type of information on the choice of the type of information was significant.

[illegible]

...the fact that the *in vitro* and *in vivo* results are in good agreement.

• **Stressors:** Stressors are the environmental factors that trigger a stress response. They can be physical (e.g., noise, temperature, light), psychological (e.g., workload, time pressure, interpersonal conflict), or social (e.g., organizational culture, job security).

...the ...

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Lichtenthaler and Whistler (1973).

[illegible]

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

1000000

[illegible]

Journal of Management Inquiry 22(1) 3–17 © The Author(s) 2013. Reprints and permissions: sagepub.com/journalsPermissions.nav

[illegible]

1. *Pharmaceuticals* (1997) 10, 11. *Pharmaceuticals* (1998) 12, 13. *Pharmaceuticals* (1999) 14, 15. *Pharmaceuticals* (2000) 16, 17. *Pharmaceuticals* (2001) 18, 19. *Pharmaceuticals* (2002) 20, 21. *Pharmaceuticals* (2003) 22, 23. *Pharmaceuticals* (2004) 24, 25. *Pharmaceuticals* (2005) 26, 27. *Pharmaceuticals* (2006) 28, 29. *Pharmaceuticals* (2007) 30, 31. *Pharmaceuticals* (2008) 32, 33. *Pharmaceuticals* (2009) 34, 35. *Pharmaceuticals* (2010) 36, 37. *Pharmaceuticals* (2011) 38, 39. *Pharmaceuticals* (2012) 40, 41. *Pharmaceuticals* (2013) 42, 43. *Pharmaceuticals* (2014) 44, 45. *Pharmaceuticals* (2015) 46, 47. *Pharmaceuticals* (2016) 48, 49. *Pharmaceuticals* (2017) 50, 51. *Pharmaceuticals* (2018) 52, 53. *Pharmaceuticals* (2019) 54, 55. *Pharmaceuticals* (2020) 56, 57. *Pharmaceuticals* (2021) 58, 59. *Pharmaceuticals* (2022) 60, 61. *Pharmaceuticals* (2023) 62, 63. *Pharmaceuticals* (2024) 64, 65. *Pharmaceuticals* (2025) 66, 67. *Pharmaceuticals* (2026) 68, 69. *Pharmaceuticals* (2027) 70, 71. *Pharmaceuticals* (2028) 72, 73. *Pharmaceuticals* (2029) 74, 75. *Pharmaceuticals* (2030) 76, 77. *Pharmaceuticals* (2031) 78, 79. *Pharmaceuticals* (2032) 80, 81. *Pharmaceuticals* (2033) 82, 83. *Pharmaceuticals* (2034) 84, 85. *Pharmaceuticals* (2035) 86, 87. *Pharmaceuticals* (2036) 88, 89. *Pharmaceuticals* (2037) 90, 91. *Pharmaceuticals* (2038) 92, 93. *Pharmaceuticals* (2039) 94, 95. *Pharmaceuticals* (2040) 96, 97. *Pharmaceuticals* (2041) 98, 99. *Pharmaceuticals* (2042) 100, 101. *Pharmaceuticals* (2043) 102, 103. *Pharmaceuticals* (2044) 104, 105. *Pharmaceuticals* (2045) 106, 107. *Pharmaceuticals* (2046) 108, 109. *Pharmaceuticals* (2047) 110, 111. *Pharmaceuticals* (2048) 112, 113. *Pharmaceuticals* (2049) 114, 115. *Pharmaceuticals* (2050) 116, 117. *Pharmaceuticals* (2051) 118, 119. *Pharmaceuticals* (2052) 120, 121. *Pharmaceuticals* (2053) 122, 123. *Pharmaceuticals* (2054) 124, 125. *Pharmaceuticals* (2055) 126, 127. *Pharmaceuticals* (2056) 128, 129. *Pharmaceuticals* (2057) 130, 131. *Pharmaceuticals* (2058) 132, 133. *Pharmaceuticals* (2059) 134, 135. *Pharmaceuticals* (2060) 136, 137. *Pharmaceuticals* (2061) 138, 139. *Pharmaceuticals* (2062) 140, 141. *Pharmaceuticals* (2063) 142, 143. *Pharmaceuticals* (2064) 144, 145. *Pharmaceuticals* (2065) 146, 147. *Pharmaceuticals* (2066) 148, 149. *Pharmaceuticals* (2067) 150, 151. *Pharmaceuticals* (2068) 152, 153. *Pharmaceuticals* (2069) 154, 155. *Pharmaceuticals* (2070) 156, 157. *Pharmaceuticals* (2071) 158, 159. *Pharmaceuticals* (2072) 160, 161. *Pharmaceuticals* (2073) 162, 163. *Pharmaceuticals* (2074) 164, 165. *Pharmaceuticals* (2075) 166, 167. *Pharmaceuticals* (2076) 168, 169. *Pharmaceuticals* (2077) 170, 171. *Pharmaceuticals* (2078) 172, 173. *Pharmaceuticals* (2079) 174, 175. *Pharmaceuticals* (2080) 176, 177. *Pharmaceuticals* (2081) 178, 179. *Pharmaceuticals* (2082) 180, 181. *Pharmaceuticals* (2083) 182, 183. *Pharmaceuticals* (2084) 184, 185. *Pharmaceuticals* (2085) 186, 187. *Pharmaceuticals* (2086) 188, 189. *Pharmaceuticals* (2087) 190, 191. *Pharmaceuticals* (2088) 192, 193. *Pharmaceuticals* (2089) 194, 195. *Pharmaceuticals* (2090) 196, 197. *Pharmaceuticals* (2091) 198, 199. *Pharmaceuticals* (2092) 200, 201. *Pharmaceuticals* (2093) 202, 203. *Pharmaceuticals* (2094) 204, 205. *Pharmaceuticals* (2095) 206, 207. *Pharmaceuticals* (2096) 208, 209. *Pharmaceuticals* (2097) 210, 211. *Pharmaceuticals* (2098) 212, 213. *Pharmaceuticals* (2099) 214, 215. *Pharmaceuticals* (2100) 216, 217. *Pharmaceuticals* (2101) 218, 219. *Pharmaceuticals* (2102) 220, 221. *Pharmaceuticals* (2103) 222, 223. *Pharmaceuticals* (2104) 224, 225. *Pharmaceuticals* (2105) 226, 227. *Pharmaceuticals* (2106) 228, 229. *Pharmaceuticals* (2107) 230, 231. *Pharmaceuticals* (2108) 232, 233. *Pharmaceuticals* (2109) 234, 235. *Pharmaceuticals* (2110) 236, 237. *Pharmaceuticals* (2111) 238, 239. *Pharmaceuticals* (2112) 240, 241. *Pharmaceuticals* (2113) 242, 243. *Pharmaceuticals* (2114) 244, 245. *Pharmaceuticals* (2115) 246, 247. *Pharmaceuticals* (2116) 248, 249. *Pharmaceuticals* (2117) 250, 251. *Pharmaceuticals* (2118) 252, 253. *Pharmaceuticals* (2119) 254, 255. *Pharmaceuticals* (2120) 256, 257. *Pharmaceuticals* (2121) 258, 259. *Pharmaceuticals* (2122) 260, 261. *Pharmaceuticals* (2123) 262, 263. *Pharmaceuticals* (2124) 264, 265. *Pharmaceuticals* (2125) 266, 267. *Pharmaceuticals* (2126) 268, 269. *Pharmaceuticals* (2127) 270, 271. *Pharmaceuticals* (2128) 272, 273. *Pharmaceuticals* (2129) 274, 275. *Pharmaceuticals* (2130) 276, 277. *Pharmaceuticals* (2131) 278, 279. *Pharmaceuticals* (2132) 280, 281. *Pharmaceuticals* (2133) 282, 283. *Pharmaceuticals* (2134) 284, 285. *Pharmaceuticals* (2135) 286, 287. *Pharmaceuticals* (2136) 288, 289. *Pharmaceuticals* (2137) 290, 291. *Pharmaceuticals* (2138) 292, 293. *Pharmaceuticals* (2139) 294, 295. *Pharmaceuticals* (2140) 296, 297. *Pharmaceuticals* (2141) 298, 299. *Pharmaceuticals* (2142) 300, 301. *Pharmaceuticals* (2143) 302, 303. *Pharmaceuticals* (2144) 304, 305. *Pharmaceuticals* (2145) 306, 307. *Pharmaceuticals* (2146) 308, 309. *Pharmaceuticals* (2147) 310, 311. *Pharmaceuticals* (2148) 312, 313. *Pharmaceuticals* (2149) 314, 315. *Pharmaceuticals* (2150) 316, 317. *Pharmaceuticals* (2151) 318, 319. *Pharmaceuticals* (2152) 320, 321. *Pharmaceuticals* (2153) 322, 323. *Pharmaceuticals* (2154) 324, 325. *Pharmaceuticals* (2155) 326, 327. *Pharmaceuticals* (2156) 328, 329. *Pharmaceuticals* (2157) 33

to the fact that the β phase is not stable at room temperature. The β phase is stable at high temperatures, and the α phase is stable at low temperatures. The β phase is the high-temperature phase, and the α phase is the low-temperature phase. The β phase is the high-temperature phase, and the α phase is the low-temperature phase.

Journal of Management Education 30(6)p.789-804



- (D) the granting of this application to produce
Ty well as a dual completion with gas from the
Ventana and gas from the Pictured Cliff is in
the interest of conservation and the protection
of correlative rights.

That the applicant will comply with all the rules
and regulations of the New Mexico Oil Conservation
Commission to maintain separation of production
from the two pay zones.

- (F) That the manner and method of this dual completion
is mechanically feasible and practical.
- (G) That by copy of this letter of application by re-
gistered mail all offset operators are notified
of this dual completion.

Therefore, Amerada Petroleum Corporation requests that the
Oil Conservation Commission grant permission to produce the subject
well as a dual completion as proposed in the application.

Respectfully submitted,

AMERADA PETROLEUM CORPORATION

By *D. C. Capps*
D. C. Capps
District Superintendent

DCC/WGA/vh

STATE OF NEW MEXICO |
COUNTY OF Lea |

Before me, the undersigned authority, on this day personally
appeared D. C. Capps, known to me to be the person whose name is sub-
scribed to this instrument, who after being by me duly sworn on oath
states that he has knowledge of all the facts stated above and that the
same is a true and correct statement of the facts recited therein.

Subscribed and sworn to before me on this the 10th
day of August, 1956.


Commission expires: August 23, 1959


[Signature]
Notary Public in and for
Lea County, New Mexico

cc: Humble Oil & Refining Company
Box 1600
Midland, Texas

Caswell Silver
323 Simms Building
Albuquerque, New Mexico

U.S. Geological Survey
P. O. Box 965
Farmington, New Mexico






AMERADA PETROLEUM CORP.

J. APACHE "F" NO. 2

990' FN & WL

Sec. 17, T-25-N, R-5-W





AMERADA PETROLEUM CORP.

Proposed Dual Completion

J. Apache "F" No. 2

Sec. 17 T-25-N R-5-W

Exhibit "B"